José Luis Castro, Executive Director of The Union, issued the following statement in response to this week’s announcement of a new clinical trial for a TB and multidrug-resistant TB treatment regimen.
The TB Alliance has announced that it plans to move into stage 3 clinical trials to test the efficacy of a new treatment regimen for tuberculosis (TB), including drug-sensitive TB and some forms of multidrug-resistant TB (MDR-TB). The regimen, known as PaMZ, is comprised of three drugs—PA-824, moxifloxacin and pyrazinamide.
The TB Alliance and its partners are proving that it’s possible to make significant advancements in the research and development of new TB treatments when the public, private and nonprofit sectors work together. Such collaboration is critical for the elimination of tuberculosis.
If successful, PaMZ will represent a dramatic improvement in the treatment regimen for tuberculosis, shortening the treatment length for MDR-TB.